MarketWatch (press release) The combination of nebivolol and valsartan demonstrated statistically significant reductions in diastolic blood pressure (DBP) vs. both neb...
4-traders (press release) The Company also reported that under its ANCHOR trial, Vascepa showed robust reductions in TGs and a broad range of other lipid parameters on top of optimized statin therapy, including atorvastatin , simvastatin, and rosuvastatin. Zakrzewski continued ... and more »
